Loading
Cincinnati's children's hospital, whose Division of Oncology takes children and young adults with hard-to-treat cancers and runs CAR T-cell and proton therapy; a Children's Oncology Group member.
The Cincinnati Children's Division of Oncology describes its focus as the hardest, most resistant childhood cancers, with patients referred from around the world. Its page credits its team science with contributions to the paediatric FDA approvals of Vyxeos for acute myeloid leukaemia and selumetinib for inoperable neurofibromatosis tumours. It offers CAR T-cell therapy for leukaemia and lymphoma, a Proton Therapy Center, next-generation sequencing to guide treatment of relapsed disease, fertility preservation, and a Young Adult Cancer Center. The page reports a No. 2 ranking for cancer care in the U.S. News & World Report 2026-2027 Best Children's Hospitals list. It is a member institution of the Children's Oncology Group.
Shares Children's Oncology Group (COG), Childhood cancers (all types), CAR-T cell therapy.
Shares Children's Oncology Group (COG), Childhood cancers (all types), CAR-T cell therapy.
Shares Children's Oncology Group (COG), Childhood cancers (all types), Proton therapy.
Shares Children's Oncology Group (COG), Childhood cancers (all types), CAR-T cell therapy.
Shares Acute myeloid leukaemia in children, Children's Oncology Group (COG), Childhood cancers (all types).
Shares Children's Oncology Group (COG), Childhood cancers (all types).
Shares Children's Oncology Group (COG), Childhood cancers (all types).
Shares Children's Oncology Group (COG), Childhood cancers (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/